CStone Pharmaceuticals
CSPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $407,205 | $463,842 | $481,363 | $243,718 |
| % Growth | -12.2% | -3.6% | 97.5% | – |
| Cost of Goods Sold | $167,051 | $159,547 | $202,985 | $106,832 |
| Gross Profit | $240,154 | $304,295 | $278,378 | $136,886 |
| % Margin | 59% | 65.6% | 57.8% | 56.2% |
| R&D Expenses | $134,657 | $527,799 | $614,162 | $1,304,945 |
| G&A Expenses | $33,165 | $48,716 | $63,175 | $109,204 |
| SG&A Expenses | $166,943 | $248,065 | $390,476 | $472,992 |
| Sales & Mktg Exp. | $133,778 | $199,349 | $327,301 | $363,788 |
| Other Operating Expenses | $30,246 | $108,276 | $185,887 | $188,392 |
| Operating Expenses | $331,846 | $884,140 | $1,190,525 | $1,966,329 |
| Operating Income | -$91,692 | -$579,845 | -$912,147 | -$1,829,443 |
| % Margin | -22.5% | -125% | -189.5% | -750.6% |
| Other Income/Exp. Net | $485 | $212,611 | $9,469 | -$90,657 |
| Pre-Tax Income | -$91,207 | -$367,234 | -$902,678 | -$1,920,100 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$91,207 | -$367,234 | -$902,678 | -$1,920,100 |
| % Margin | -22.4% | -79.2% | -187.5% | -787.8% |
| EPS | -0.072 | -0.29 | -0.77 | -1.65 |
| % Growth | 75.3% | 62.3% | 53.3% | – |
| EPS Diluted | -0.072 | -0.29 | -0.77 | -1.65 |
| Weighted Avg Shares Out | 1,276,198 | 1,263,075 | 1,172,309 | 1,163,697 |
| Weighted Avg Shares Out Dil | 1,276,198 | 1,263,073 | 1,172,839 | 1,165,209 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,667 | $24,886 | $9,672 | $9,803 |
| Interest Expense | $15,167 | $11,819 | $8,477 | $2,242 |
| Depreciation & Amortization | $49,805 | $58,190 | $44,540 | $22,661 |
| EBITDA | -$26,235 | -$297,225 | -$849,661 | -$1,895,197 |
| % Margin | -6.4% | -64.1% | -176.5% | -777.6% |